Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement Surgery
Status:
Completed
Trial end date:
2007-06-01
Target enrollment:
Participant gender:
Summary
The primary objective was to demonstrate the dose-response of Semuloparin sodium (AVE5026)
for the prevention of Venous Thromboembolism [VTE] in patients undergoing total knee
replacement [TKR] surgery.
Secondary objectives were to evaluate the safety (incidence of major bleeding) of AVE5026, to
document the efficacy and safety of AVE5026 post-operative regimens, and to assess the
pharmacokinetic parameters of AVE5026.